NCT00018603已完成1 期
Guanfacine for the Treatment of PTSD
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and second, to explore neurobiological mechanisms of action of guanfacine.
详细描述
Subject population is comprised of 100 persons with PTSD. 50 patients will receive guanfacine and 50 patients will receive a placebo. Guanfacine is prescribed at 1 mg/day and may be increased to 2 mg/day. Samples of plasma MHPG will be collected weekly. Clinical ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly. Repeated measures analysis of variance will assess significance of main effect of drug, time, and drug by time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females, age 18-65
- •Diagnosis of PTSD from combat or civilian trauma
- •No major medical problems such as diabetes, cardiovascular disease
- •Taking no psychiatric medication, or taking only one SSRI antidepressant
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive DisorderMajor Depressive DisorderNCT01355081Takeda366
终止
1 期
A mGlu2/3 Agonist in the Treatment of PTSDPost-traumatic Stress DisorderNCT02234687NYU Langone Health10
已完成
不适用
The Effects of Bifidobacterium Longum 1714® in a Population With Low MoodLow MoodDepressive SymptomsNCT04925440PrecisionBiotics Group Ltd.168
撤回
4 期
Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi SyndromePrader-Willi SyndromeNCT04066088NYU Langone Health
已完成
3 期
Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)Major Depressive DisorderNCT00683592Forest Laboratories481